
Avalon Pharmaceuticals (AVRX) is collaborating with ChemDiv to discover, develop and commercialize small-molecule drugs for cancer.
Under the terms of the deal, Avalon will use its AvalonRx® platform, and access ChemDiv's Discovery outSource™ services platform, as well.
Avalon also gains the right to select 200,000 compounds from the ChemDiv library for use in all of Avalon's discovery programs.
Source: Avalon press release.



.jpg)



Comment Preview